Britain's GSK said on Monday it would invest 130 million pounds ($163 million) to buy a 10 percent stake in Germany's CureVac, launching a collaboration to develop up to five mRNA-based vaccines with technology already being used by the biotech company to develop a COVID-19 vaccine.
CureVac's existing COVID-19 mRNA and rabies vaccines research programmes are not included in the deal, the companies said.
CureVac said in June it would start human trials of an experimental vaccine for treating COVID-19 in the country.
The company, based in Tuebingen and backed by the Bill & Melinda Gates Foundation, is using the so-called messenger RNA approach that has also been adopted by BioNTech and its partner Pfizer as well as Moderna.
Follow our full coverage of the coronavirus pandemic here.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
